Unacknowledged Casualties

The Issue

What Happened, Who Was Harmed, and Why It Matters Now

2.1 What Happened

Between 1998 and 2002, the Australian Defence Force deployed approximately 3,000 personnel to East Timor and Bougainville. As part of those deployments, personnel were administered two antimalarial drugs: mefloquine (brand name Lariam) and tafenoquine. In significant part, these were formal clinical drug trials conducted by the Army Malaria Institute (AMI).

The scale of the trials was substantial. An estimated 1,319 ADF personnel participated in mefloquine trials in East Timor alone. More than 1,540 were enrolled in tafenoquine studies across both deployment theatres. Records specific to Bougainville remain less publicly documented than those from East Timor, and the full picture of that deployment's trial conduct has not been independently established.

The dosing conditions were extreme by any clinical standard. The standard TGA-approved prophylactic dose of mefloquine is 250 mg per week. During the AMI trials, personnel were administered loading doses of 750 mg per week; in some documented cases, trial subjects received loading doses of up to 1,500 mg per week — six times the approved level. Tafenoquine trial subjects received up to 1,200 mg over three days.

Personnel were not always adequately informed of what they were being given or why. Many were not informed at all. No consent process meeting contemporary clinical trial standards was applied. No longitudinal follow-up health studies have ever been conducted on the tafenoquine trial subjects (McCarthy, QVFA Submission 94).

Evidential register

Status: Established. Drawn from ADF parliamentary submissions, Senate inquiry records, and the Royal Commission Final Report (2024). Specific dosing figures sourced from the QVFA Senate submission (McCarthy, Submission 94) and should be verified against primary AMI trial records where relied upon for legal or formal purposes. The absence of Bougainville-specific longitudinal data is stated as a documented gap, not established fact.

2.2 What the Drugs Can Do

Both mefloquine and tafenoquine are now recognised by major regulatory agencies as carrying substantial neuropsychiatric risk.

In 2013, the United States Food and Drug Administration issued a black box warning — its most serious category of drug safety alert — for mefloquine. The warning states explicitly that neuropsychiatric adverse reactions may persist after the drug is discontinued and may in some cases become permanent. Listed psychiatric effects include anxiety, paranoia, depression, hallucinations, psychotic behaviour, and suicidal ideation. Listed neurological effects include dizziness, vertigo, tinnitus, and loss of balance that may persist for months or years, or become permanent. The Australian Therapeutic Goods Administration and the European Medicines Agency have issued parallel strengthened warnings.

In 2009, researchers at the Walter Reed Army Institute of Research — the institution that developed both drugs — found tafenoquine to be more neurotoxic than mefloquine in laboratory studies. Mefloquine was by that point already classified by the ADF as a drug of last resort.

The harms documented among affected veterans include chronic depression, anxiety, paranoia, delusional disorder, psychosis, hallucinations, personality change, aggression, dissociation, vestibular disorders, seizures, and suicide.

These harms are not limited to the veteran. They extend into the household.

The documented harm includes domestic violence, coercive control, and lethal family violence directed at partners and children — consequences that have received almost no dedicated institutional attention in Australia. To date, no domestic violence policy, no family law framework, and no coroner's protocol has been developed in response to the specific neuropsychiatric risk profile of this cohort.

Evidential register

Status: Established (regulatory) / Plausible mechanism with documented case evidence (domestic violence nexus). FDA black box warning, TGA and EMA documentation, and peer-reviewed literature establish the neuropsychiatric risk profile. The connection to domestic violence is supported by documented case evidence and plausible neurological mechanism; direct causation is not asserted beyond what the peer-reviewed literature supports. The absence of relevant policy frameworks is stated as a structural gap on the public record.

2.3 Who This Site Is About

Every existing framework — the DVA claims system, the military welfare architecture, the Royal Commission's recommendations, the brain injury program currently being developed — is oriented toward the veteran as the subject of harm and the subject of entitlement.

This site does not diminish that. The veteran's suffering is real, documented, and still inadequately addressed.

But the veteran is not the only person who was harmed.

The partner who came home to someone changed did not choose this. She did not deploy. She did not consent to participate in a drug trial. She was not briefed on the potential neuropsychiatric risks of the compounds administered to her partner. She signed no form. No institution monitored her welfare. No system exists to recognise her injury.

She lived — sometimes for years, sometimes for decades — in a household where the person she loved had been neurologically altered by a government drug trial, and where the institutions responsible for that trial have never acknowledged her existence as an affected party.

This site begins with her.

A note on framing This site does not attribute moral blame to veterans for behaviour that the evidence suggests may originate in documented pharmacological injury. Neurologically injured people are not morally responsible for changes in behaviour they did not choose and were not warned about. The harm documented here is systemic. It originates with the decision to administer potent neurotoxic compounds without adequate consent, monitoring, or follow-up care.

This site uses "she" and "her" when referring to the partner or spouse, reflecting the documented evidence base in which affected partners are predominantly women. This framing does not exclude male partners of female veterans or others outside this pattern; it follows the demographic reality of the cohort as documented in Senate submissions, advocacy records, and case evidence.

2.4 Why It Matters Now

The Royal Commission into Defence and Veteran Suicide tabled its Final Report in September 2024. For the first time, mefloquine and tafenoquine received dedicated official attention at that level: Volume 4, Chapter 22 examined the drugs, the trials, and the harm, and recommended that Defence and DVA establish a brain injury program for affected veterans.

In December 2024, the Australian Government accepted or agreed in principle to 104 of the Commission's 122 recommendations. Work on the brain injury program is reported to be underway.

This is genuinely significant progress. The position that for two decades characterised the dominant institutional response — that quinoline toxicity was not a legitimate medical issue warranting systemic acknowledgement — is no longer the government's stated position.

But several things remain unchanged. Five structural gaps persist that directly affect families — each addressed in the recommendations on the What Must Change page:

The brain injury program does not yet extend to spouses, partners, or children.
The Statement of Principles gap for acquired brain injury in the DVA entitlements system has not been resolved.
Domestic violence services have received no guidance or training specific to quinoline-related neurotoxicity.
Family law courts operate without any framework for understanding the neurological context of post-trial veteran behaviour.
Coroners investigating deaths in ADF veteran families are not required to obtain pharmaceutical records from the Army Malaria Institute.

The Royal Commission asked the right questions about veterans. The questions about their families have not yet been asked — let alone answered.

This site documents what those questions are, what the evidence says, and what must change.

Evidential register

Status: Established (Royal Commission findings and government response) / Structural analysis (remaining gaps). Royal Commission Final Report (2024) and the December 2024 government response are public record. The characterisation of the prior institutional position is based on documented Senate submissions, DVA correspondence, and advocacy records spanning 2004–2023; "dominant institutional response" is used in preference to "flat denial" to reflect the documented range of official positions across that period. The five remaining gaps are stated as structural absences on the public record — documented by the presence of frameworks that do not address these cohorts, rather than by explicit policy exclusion.